Good baseline visual acuity retained in three-fourths of patients at 36 weeks with OTX-TKI ...

A retinal implant developed by Science Corp. has for the first time restored some functional vision to patients with a severe form of age-related macular degeneration (AMD), a common eye disease and ...

A groundbreaking retinal implant system has helped most patients with advanced age-related macular degeneration regain meaningful vision in a clinical trial. The study, published in The New England ...

A phase III trial found that the sustained-release VEGF inhibitor implant OTX-TKI preserved visual acuity and retinal anatomy in wet age-related macular degeneration better than standard aflibercept ...

PITTSBURGH, October 20, 2025 – A wireless retinal implant can restore central vision in patients with advanced age-related macular degeneration (AMD), according to clinical trial results published ...

For the first time, a vision-restoration effort has achieved successful outcomes in a significant number of patients. Clinical trial findings recently published in the New England Journal of Medicine ...

With three potential blockbuster drugs for retinal disease receiving regulatory approval in 2023, 2024 may feel quiet by comparison for the field. However, retina specialists may feel like they have ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...